<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4395">
  <stage>Registered</stage>
  <submitdate>18/01/2013</submitdate>
  <approvaldate>18/01/2013</approvaldate>
  <nctid>NCT01786512</nctid>
  <trial_identification>
    <studytitle>COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.</studytitle>
    <scientifictitle>A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction</scientifictitle>
    <utrn />
    <trialacronym>COSMIC-HF</trialacronym>
    <secondaryid>20110151</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Modified Release Oral Formulation</healthcondition>
    <healthcondition>Left Ventricular Systolic Dysfunction</healthcondition>
    <healthcondition>Chronic Heart Failure</healthcondition>
    <healthcondition>History of Chronic Heart Failure</healthcondition>
    <healthcondition>Left Ventricular Ejection Fraction</healthcondition>
    <healthcondition>Pharmacokinetics</healthcondition>
    <healthcondition>Echocardiogram</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Omecamtiv Mecarbil
Treatment: drugs - Omecamtiv Mecarbil
Treatment: drugs - Placebo
Treatment: drugs - Omecamtiv Mecarbil
Treatment: drugs - Omecamtiv Mecarbil

Experimental: Omecamtiv mecarbil - 

Placebo Comparator: Placebo - 


Treatment: drugs: Omecamtiv Mecarbil
Oral omecamtiv mecarbil dose of 25-mg BID for 7 days

Treatment: drugs: Omecamtiv Mecarbil
Oral omecamtiv mecardbil dose of 50-mg BID for 7 days.

Treatment: drugs: Placebo
Placebo

Treatment: drugs: Omecamtiv Mecarbil
Oral omecamtiv mecarbil dose of 25-mg BID for 20 weeks.

Treatment: drugs: Omecamtiv Mecarbil
Oral omecamtiv mecarbil dose of 25 mg BID for 8 weeks followed by 50-mg BID for 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose Escalation - Characterize Pharmacokinetics - Cmax - Maximum Observed Plasma Concentration (Cmax)</outcome>
      <timepoint>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 96, 120 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 168 hours following dose on day 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose Escalation - Characterize Pharmacokinetics -Cmin - Minimum Observed Concentration (Cmin)</outcome>
      <timepoint>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 96, 120 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 168 hours following dose on day 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose Escalation - Characterize Pharmacokinetics-Tmax - Time to Reach Maximum Plasma Concentration (Tmax)</outcome>
      <timepoint>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 96, 120 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 168 hours following dose on day 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose Escalation - Characterize Pharmacokinetics - AUC12h - Area under the curve until 12 hours after investigational product (IP) administration (AUC12h)</outcome>
      <timepoint>0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours following dose on day 7</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose Expansion - Characterize Pharmacokinetics - Cmax - Maximum Observed Plasma Concentration (Cmax)</outcome>
      <timepoint>predose, predose, 1 , 2, 4, 6, and 8 hours after morning dose on weeks 2 and 12; predose, between 1-4 hours post dose on week 20</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose Expansion - Characterize Pharmacokinetics - Cpredose - Concentration prior to IP administration (Cpredose)</outcome>
      <timepoint>predose before morning dose on Day1, weeks 2, 8 , 12, 16 and 20</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Systolic Ejection Time(SET) (msec) - Changes from baseline in Systolic Ejection Time (SET)</outcome>
      <timepoint>baseline and 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Left Ventricular End-Systolic Diameter (LVESD) (cm) - Changes from baseline in Left Ventricular End-Systolic Diameter (LVESD)</outcome>
      <timepoint>baseline and 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Left Ventricular End-Diastolic Diameter (LVEDD) (cm) - Changes from baseline in Left Ventricular End-Diastolic Diameter (LVEDD)</outcome>
      <timepoint>baseline and 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart Rate (beats per minute) - Changes from baseline in heart rate</outcome>
      <timepoint>baseline and 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stroke Volume (ml) - Changes from baseline in Stroke Volume</outcome>
      <timepoint>baseline and 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of omecamtiv mecarbil on NT-proBNP (pg/mL) - To evaluate the effect of 12 weeks of oral dosing with omecamtiv mecarbil on Nterminal pro-B-type natriuretic peptide (NT-proBNP)</outcome>
      <timepoint>baseline and 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dose Escalation - Safety and tolerability of oral omecamtiv mecarbil - Subject incidence of adverse events from baseline to 35 days (end of study)</outcome>
      <timepoint>baseline to 35 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dose Expansion - Safety and tolerability of oral omecamtiv mecarbil - Subject incidence of adverse events from baseline to week 24 (end of study)</outcome>
      <timepoint>baseline to 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  History of chronic HF, defined as requiring treatment for HF for a minimum of 4 weeks
             prior to screening

          -  Treated with stable, optimal pharmacological therapy for = 4 weeks

          -  History of left ventricular ejection fraction (LVEF) = 40%

          -  Elevated N-terminal fragment BNP (NT-proBNP)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Severe uncorrected valvular heart disease

          -  Hospitalization within 30 days prior to enrollment

          -  Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive
             pericarditis, or clinically significant congenital heart disease

          -  Acute Myocardial Infarction, Unstable angina or persistent angina at rest within 30
             days prior to randomization

          -  Systolic BP &gt; 160 mmHg or &lt; 90 mmHg or diastolic BP &gt; 90 mmHg

          -  TBL = 2x ULN; AST or ALT = 3x ULN

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>26/02/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>544</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>19/08/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,WA</recruitmentstate>
    <hospital>Research Site - Darlinghurst</hospital>
    <hospital>Research Site - Nedlands</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ieper</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Kazanlak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pazardzhik</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sandanski</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sliven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Smolyan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Svitavy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Teplice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Nauheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Greifswald</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Jaszbereny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Zalaegerszeg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Vilnius</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amersfoort</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Klodzko</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Ruda Slaska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dudley</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Harrow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Cytokinetics</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objectives of this study are (i) to select an oral modified release (MR)
      formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in subjects
      with HF and left ventricular systolic dysfunction and (ii) to characterize its
      pharmacokinetics (PK) over 20 weeks of treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01786512</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>